FAS REPORTED THAT THERE ARE NO REASONS FOR THE RISE IN PRICES FOR VITAL MEDICINE

12-07-2021 | 10:53

Media allegations on the rise in medicine prices are manipulative in nature since a rise in prices for vital medicine is impossible due to regulatory aspects

The FAS Russia warns officials of baseless allegations on the rise in medicine prices. Such allegations can lead to artificial stimulation of the demand for vital medicine.

The antimonopoly service recalls that the prices for medicine included in the list of vital essential medicine are regulated by the state and cannot be higher than the established limits.

To date, a balanced pricing system designed to prevent pharmaceutical manufacturers from rising prices for vital medicine and, at the same time, preserve the profitability of their production and supply, has been built in Russia.

To prevent the shortage of vital medicine due to the unprofitability of their production, the Government of the Russian Federation adopted Resolution No. 1771. The mechanism prescribed in the document allows not only to identify a possible shortage of vital medicine in advance but also to set prices for them at an economically reasonable level and thereby ensure their presence in the market.

To date, the FAS Russia has already set 61 new economically reasonable prices for 22 medicines, ensuring their presence in the market. In particular, we are talking about the prices for such vital medicine as "etoposide", "vincristine", "penicillamine" and "cyproterone".

 

For reference:

The antimonopoly service revised more than 14 thousand prices for vital medicine in 2020. The FAS Russia compared the prices at which the medicine are being sold by pharmaceutical companies in Russia to the prices for the same medicine in the benchmark countries [1].

As a result of the review, the FAS Russia reduced 7 thousand prices for vital medicine at an economically reasonable level, that is, at the level of benchmark countries against Russia. On average, the price reduction was equal to 35%.

[1] Benchmark countries are the countries with similar economies in healthcare, the principles of price regulation and medicine provision. The list of these countries is approved by the Government of the Russian Federation.



Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do General Information Institutional Memory Mission, Goals, Values Priority Setting Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings GCR Using our website International Cooperation Treaties & Agreements OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 OECD meetings 2018 OECD meetings 2019 OECD meetings 2020 OECD meetings 2021 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 15th session IGE UNCTAD 16th session IGE UNCTAD 17th session IGE UNCTAD 18th session IGE UNCTAD 8th UN Conference on Competition 19th session IGE UNCTAD EEU Model Law on Competition ICN BRICS BRICS Conferences Documents The BRICS Competition Law and Policy Centre (BRICS Competition Centre) BRICS Working Groups for the research of competition issues in socially important markets The Working Group for Research on the Competition Issues in the Pharmaceutical Markets Chair: Russia The Working Group for Research on food value chains Chair: South Africa The Working Group for Research on the Competition Issues in the Automobile Markets Co-chaired: India, South Africa The Working Group for Research on the Competition Issues in the Digital Markets Co-chairs: Brazil, Russia BRICS Coordination Committee on antimonopoly policy EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Document Library Legislation Reports & Analytics Cases & decisions Contacts Give feedback Contact us Links Authorities Worldwide COVID-19